America’s drug safety agency declined to review a next-gen flu vaccine that uses the same tech as the coronavirus shots ...

After initially rejecting Moderna’s application for review, the FDA will now consider the company’s mRNA flu shot ...

The disagreement between Moderna and the FDA has reached a resolution just eight days after the biotech received a Refusal-to ...

After the FDA’s decision to reject a review of Moderna’s mRNA-1010 flu shot, executives explain what Americans will miss out ...

After an initial rejection, the FDA will review Moderna’s mRNA flu vaccine for adults 50+, aiming for approval by the 2026-27 season.

Following a prior Refusal-to-File and Type A meeting, the FDA's CBER will proceed to review BLA for mRNA-1010.

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel ...

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday ...

Add Yahoo as a preferred source to see more of our stories on Google. Health and Human Services Secretary Robert F. Kennedy Jr. canceled $500 million of funding for research on mRNA vaccine technology ...

Moderna claimed that the decision, issued by top vaccine regulator Vinay Prasad, was “inconsistent” with prior FDA ...